An observational study in Diabetes Mellitus, Type 2, Obesity and Chronic Kidney Disease, sponsored by Novo Nordisk A/S. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Novo Nordisk A/S · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S — 27 open to participants now, 31 under way, 11 of them phase 3. Diabetes Mellitus, Type 2 · Novo Nordisk A/S.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one has the largest planned enrollment of the 215 observational ones that give a count, is one of 25 that started in 2026, is one of 215 observational ones, reaches primary completion later than 0 of the 30 other live ones, and was the 631st registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →27 of the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 25–69 · Healthy volunteers
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States, Argentina, Brazil and 13 more countries
Ages 45+
By country, each count listing its studies:
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 19 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
645 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 131 · Phase 2 38 · Phase 3 187 · Phase 4 75
First in 1997; this study’s year is marked. 25 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 800,000 is above the median of 300 across 1,749 observational studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 209 across the 430 interventional studies, 938 across the 215 observational. Of the 603 that completed or were terminated, 174 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,411 studies on the registry; 108 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
8 of the studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07817251Phase 3Novo Nordisk A/SResearch Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | 2027-06-09 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT05689372Novo Nordisk A/SRegulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | 2026-11-30 |
| NCT07532863Novo Nordisk A/SA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants | 2027-03-27 |
Add all 8 to your calendar (.ics) → With an account.
Among the 645 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease [MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.
The participants in this study are drawn from Korean National Health Insurance Service (NHIS) - National Sample Cohort (NSC) aged 19 years and older. The eligible participants were selected by stratified random sampling in 2006 with follow-up through December 2023.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Primary Analysis:
Secondary Analysis (Subgroup Cohorts):
Exclusion Criteria:
Primary Analysis:
Secondary Analysis (Subgroup Cohorts)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with MASLD where the date of first MASLD identification at biennial screening (2013-2018), after the greater than or equal to (≥) 1-year washout window; follow-up continues until death, loss of NHIS eligibility, or end of available data.
Other: No treatment given
Participants for whom the date of first HF diagnosis is at biennial screening (2013-2028), after the ≥1-year washout window; follow-up continues for a minimum of 5 years from the index date.
Other: No treatment given
Participants were categorized according to CKM staging (Stages 0-4), based on their CKM stage assessed at the initial national health screening, after the ≥1-year washout window; follow-up continues until death, loss of National Health Insurance Service (NHIS) eligibility, or end of available data.
Other: No treatment given
Participants with pre-specified obesity participants of interest tier that indicating significant overweight and were classified into three categories: 1) Body Mass Index (BMI) greater than or equal to (≥) 27 kg/m\^2 with established CVD. 2) BMI ≥27 kg/m\^2 with one or more obesity-related comorbidities. 3) BMI ≥25 kg/m\^2 and less than (\<) 30 kg/m\^2 with 1 or more obesity-related comorbidities.
Other: No treatment given
Participants with ASCVD where the first ASCVD identification occurred during biennial screening (2013-2018), after the ≥1-year washout window.
Other: No treatment given
No treatment given
Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2))
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with T2D
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with hypertension
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with dyslipidemia
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with CKD
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Proportion of participants with Osteoarthritis (OA)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Multi-disease overlap (≥2, ≥3 conditions)
Measured in proportion (%).
Time frame: 2013-2018 (Annually)
Patient characteristics in obesity/diabetes-anchored strata
Measured as descriptive statistics.
Time frame: 2013-2018 (Annually)
Baseline characteristics by subgroup cohort
Measured as descriptive statistics.
Time frame: Cohort index date (2013-2018)
All-cause mortality over cohort follow-up
Measured in Hazard Ratio (HR).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential follow up (FU))
Healthcare resource utilization (HCRU) over cohort follow-up (Number of participants)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of number of participants.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Healthcare resource utilization (HCRU) over cohort follow-up (rates per person-year)
Measured as outpatient visits, hospitalizations, and emergency room visits in terms of rates per person-year.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Total medical costs over cohort follow-up (Mean)
Measured as Cumulative total costs and annualized costs per person-year in terms of means with standard deviations.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Total medical costs over cohort follow-up (Median)
Measured as Cumulative total costs and annualized costs per person-year in terms of medians with Interquartile Range (IQR)
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential FU)
Three-point major adverse cardiovascular events (3P-MACE) composite assessment for CV-death proxy, non-fatal myocardial infarction, and non-fatal stroke
Measured in Hazard Ratio (HR).
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 yr potential (FU)
Proportion of participants with baseline organ-axis phenotype distribution (HF cohort): ASCVD, renal, metabolic, hepatic axes
Measured in proportion (%) by phenotype.
Time frame: Cohort index date (2013-2018)
Proportion of participants with GDMT prescription patterns, calendar-year trends, and prescription disparities (HF cohort)
Measured in proportion (%).
Time frame: Over cohort follow-up (2013-2023)
Time to CKM stage progression (CKM stage cohort)
Measured as median time to progression, if estimable; number and proportion with progression
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to date of Progression
Time to tier change (High obesity cohort)
Measured as median time to tier change, if estimable; number and proportion with tier change.
Time frame: From cohort index date (entry restricted to 2013-2018; ≥5 years potential FU) to tier change
Started Jun 2026 (actual). Primary completion is estimated for Aug 2026, 1 month after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.